Search

Your search keyword '"Ferraro, Diana"' showing total 525 results

Search Constraints

Start Over You searched for: Author "Ferraro, Diana" Remove constraint Author: "Ferraro, Diana"
525 results on '"Ferraro, Diana"'

Search Results

1. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis

2. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression

3. Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression

4. ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis

5. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients

6. Late-onset multiple sclerosis: disability trajectories in relapsing–remitting patients of the Italian MS Registry

7. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

8. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

10. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

11. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study

12. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

13. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab

14. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

15. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

16. SARS-CoV-2 Vaccination Responses in Anti-CD20-Treated Progressive Multiple Sclerosis Patients Show Immunosenescence in Antigen-Specific B and T Cells.

17. Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

19. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

20. Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).

21. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

22. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

23. Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

24. Cell-based assays for the detection of MOG antibodies: a comparative study

25. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

27. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

28. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

30. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

31. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

32. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

33. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

35. Multiple Sclerosis Progression and Relapse Activity in Children.

36. Effectiveness of multiple disease- modifying therapies in relapsing- remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.

39. Disability accrual in primary and secondary progressive multiple sclerosis

41. Comparative effectiveness in multiple sclerosis: A methodological comparison

42. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

43. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study

44. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

45. “Better explanations” in multiple sclerosis diagnostic workup: A 3-year longitudinal study

47. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study

48. Disability accrual in primary and secondary progressive multiple sclerosis

49. Definitive childlessness in women with multiple sclerosis: a multicenter study

50. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band

Catalog

Books, media, physical & digital resources